Add to ORKGThe crosstalk between hormone- and EGFR-family pathways is considered a possible cause of hormone-resistance. To evaluate the effects of a combined blockade of these two pathways, we activated an international multicentre phase IIb double blind randomized trial in neoadjuvant setting
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is esta...
Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2...
Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2...
The crosstalk between hormone- and EGFR-family pathways is considered a possible cause of hormone-re...
Background: Crosstalk between hormone- and EGFR-family pathways is a possible cause of resistance to...
Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a cro...
Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a cro...
Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a cro...
Background: The crosstalk between the ER pathway and erbB receptor family is emerging as a mechanism...
Background: In HR+ve BC, the simultaneous blockade of ER and HER-related pathways could prevent the ...
Background: This is a randomized, double-blind, placebo controlled study aimed to evaluate the clini...
Purpose This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical ...
Background: This is a randomized, double-blind, placebo controlled study aimed to evaluate the clini...
International audiencePURPOSE: Cross-talk between human epidermal growth factor receptors and hormon...
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is esta...
Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2...
Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2...
The crosstalk between hormone- and EGFR-family pathways is considered a possible cause of hormone-re...
Background: Crosstalk between hormone- and EGFR-family pathways is a possible cause of resistance to...
Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a cro...
Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a cro...
Many hormone receptor-positive tumors show primary or acquired resistance, possibly because of a cro...
Background: The crosstalk between the ER pathway and erbB receptor family is emerging as a mechanism...
Background: In HR+ve BC, the simultaneous blockade of ER and HER-related pathways could prevent the ...
Background: This is a randomized, double-blind, placebo controlled study aimed to evaluate the clini...
Purpose This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical ...
Background: This is a randomized, double-blind, placebo controlled study aimed to evaluate the clini...
International audiencePURPOSE: Cross-talk between human epidermal growth factor receptors and hormon...
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is esta...
Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2...
Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2...